Literature DB >> 26414608

Using multiparametric MRI to 'personalize' biopsy for men.

Neil Mendhiratta1, Xiaosong Meng, Samir S Taneja.   

Abstract

PURPOSE OF REVIEW: In recent years, multiparametric magnetic resonance imaging (mpMRI) of the prostate has shown promise as a modality to identify areas of suspicion within the gland which correlate with cancer location and disease extent. However, optimal individualization of prostate biopsy using mpMRI relies on aligning the relative benefits of MRI-targeted approaches with the goals of biopsy. RECENT
FINDINGS: For men with prior negative biopsies, mpMRI allows improved detection of occult high-grade cancers missed by repeat systematic biopsy but also has the potential to identify men who will not benefit from repeat biopsy due to a low likelihood of significant disease. For men with prior low-grade cancer diagnosis, the addition of MRI-targeted biopsy may identify those who are poor candidates for active surveillance by detecting high-risk disease without serial biopsies. For men without prior biopsy, mpMRI and targeted biopsy may help improve high-grade cancer diagnosis and significantly limit the detection of low-risk disease.
SUMMARY: mpMRI of the prostate is a promising tool to address many of the shortcomings of traditional systematic prostate biopsy. Biopsy history plays a critical role in determining how to assess the potential advantages and disadvantages of prostate mpMRI in the context of each patient. Although these benefits have been suggested by published clinical outcomes data, there is a need for prospective validation of mpMRI and MRI-targeted biopsy in comparison with the current approach of systematic biopsy for all men, to define new paradigms for prostate cancer detection and risk stratification.

Entities:  

Mesh:

Year:  2015        PMID: 26414608     DOI: 10.1097/MOU.0000000000000216

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  6 in total

1.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

2.  Management of prostate cancer: NYU Case of the Month, July 2017.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2017

3.  Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Daniele Mattevi; Leonardo Bizzotto; Irene Tamanini; Maria A Cerruto; Guido Martignoni; Matteo Brunelli; Walter Artibani
Journal:  Curr Urol       Date:  2017-07-30

4.  Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.

Authors:  Michael S Manak; Jonathan S Varsanik; Brad J Hogan; Matt J Whitfield; Wendell R Su; Nikhil Joshi; Nicolai Steinke; Andrew Min; Delaney Berger; Robert J Saphirstein; Gauri Dixit; Thiagarajan Meyyappan; Hui-May Chu; Kevin B Knopf; David M Albala; Grannum R Sant; Ashok C Chander
Journal:  Nat Biomed Eng       Date:  2018-09-17       Impact factor: 25.671

Review 5.  Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach.

Authors:  Chau Hung Lee; Teck Wei Tan; Cher Heng Tan
Journal:  Korean J Radiol       Date:  2021-04-01       Impact factor: 3.500

Review 6.  MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?

Authors:  Ivo G Schoots
Journal:  Transl Androl Urol       Date:  2018-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.